𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The use of adalimumab for cricoarytenoid arthritis in ankylosing spondylitis—an effective therapy

✍ Scribed by Gauthier Desuter; Thierry Duprez; Caroline Huart; Quentin Gardiner; Gust Verbruggen

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
760 KB
Volume
121
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This report describes cartilaginous regeneration in a cricoarytenoid joint affected by spondyloarthropathy using tumor necrosis factor‐alpha (TNF‐α) blockade, monitored by magnetic resonance (MR) and computed tomography (CT) imaging. This case is interesting for several reasons. It is only the eighth case of destructive ankylosing spondylitis‐related cricoarytenoid arthritis published in the English language literature. It describes, for the first time, full recovery of vocal cord mobility following TNF‐α blockade. It is also the first case to be published with MR imaging demonstrating regeneration of the cricoarytenoid cartilage following treatment. This case represents a landmark in the treatment of patients presenting with destructive arthritis involving the cricoarytenoid joint.

📜 SIMILAR VOLUMES

Adalimumab for long-term treatment of ps
Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial
✍ Dafna D. Gladman; Philip J. Mease; Christopher T. Ritchlin; Ernest H. S. Choy; J 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti–tumor necrosis factor (anti‐TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA). ## Methods Patients who completed the Adalimumab Effect